Triple Therapy to Outwit the BRAF Oncogene

Cancer Discov. 2021 Jul;11(7):1620-1622. doi: 10.1158/2159-8290.CD-21-0378.

Abstract

BRAF-mutant cancers have been knocked down by BRAF and MEK inhibitor combos, yet the cancers always find a way to get back up. Adding a third medicine, namely, a dimer-selective BRAF inhibitor, can knock down longer and better.See related article by Adamopoulos et al., p. 1716.

Publication types

  • Comment

MeSH terms

  • Humans
  • Oncogenes*
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf* / genetics

Substances

  • Protein Kinase Inhibitors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf